At the time of writing, Mineralys Therapeutics Inc [MLYS] stock is trading at $13.75, up 2.46%. An important factor to consider is whether the stock is rising or falling in short-term value. The MLYS shares have lost -1.01% over the last week, with a monthly amount glided 8.87%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on July 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on April 02, 2024, and set its price target to $30. On March 07, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 07, 2023. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on March 07, 2023. In a note dated March 07, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $40 on this stock.
For the past year, the stock price of Mineralys Therapeutics Inc fluctuated between $5.85 and $16.91. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $13.75 at the most recent close of the market. An investor can expect a potential return of 118.18% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.32 and Total Capital is -0.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.28 points at the first support level, and at 12.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.08, and for the 2nd resistance point, it is at 14.40.
Ratios To Look Out For
It is important to note that Mineralys Therapeutics Inc [NASDAQ:MLYS] has a current ratio of 18.06. On the other hand, the Quick Ratio is 18.06, and the Cash Ratio is 4.71.
Transactions by insiders
Recent insider trading involved Rodman David Malcom, Chief Medical Officer, that happened on Jul 16 ’24 when 525.0 shares were sold. Chief Executive Officer, Congleton Jon completed a deal on Jul 11 ’24 to sell 15746.0 shares. Meanwhile, CFO and Secretary Levy Adam Scott sold 10757.0 shares on Jul 11 ’24.
